Synlogic Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$278.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Synlogic Therapeutics's estimated annual revenue is currently $16.1M per year.(i)
  • Synlogic Therapeutics received $30.0M in venture funding in April 2018.
  • Synlogic Therapeutics's estimated revenue per employee is $155,000
  • Synlogic Therapeutics's total funding is $278.9M.

Employee Data

  • Synlogic Therapeutics has 104 Employees.(i)
  • Synlogic Therapeutics grew their employee count by 2% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.2M1-99%N/AN/A
#2
$3.1M20233%N/AN/A
#3
$21.5M13918%$351MN/A
#4
$18M1165%$312.8MN/A
#5
$235M418-23%$340.9MN/A
#6
$2.2M3417%N/AN/A
#7
$6M40-9%$176.5MN/A
#8
$109.4M70614%N/AN/A
#9
$6.2M40233%N/AN/A
#10
$1.9M12-20%N/AN/A

At Synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. Using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. We can deliver these synthetic biotics orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. We also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. We can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. Our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (UCD) and phenylketonuria (PKU). We are also hard at work on synthetic biotics to address more prevalent conditions, including inflammatory bowel disease (IBD), cancer and metabolic conditions such as diabetes and obesity. Learn more on our website at www.synlogictx.com.

keywords:Licensing,Biotechnology,Healthcare,Pharmaceuticals

$278.9M

Total Funding

104

Number of Employees

$16.1M

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Synlogic Therapeutics News

2022-04-19 - CBRE Hires Top Boston Life Sciences Broker From JLL

His clients have included occupiers such as Arrakis Therapeutics, Synlogic Therapeutics and Celgene, and he has represented landlords such...

2022-04-17 - CBRE Hires Don Domoretsky to Join its Life Sciences ...

... occupiers including Arrakis Therapeutics, Synlogic Therapeutics, Celgene, MISPRO Biotech, and Cerevel Therapeutics, among others.

2022-03-30 - Synlogic to Present Data on Phenylketonuria and ...

Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit,...

2021-07-15 - Synlogic : Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketonuria (PKU) (Form 8-K)

Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketonuria (PKU) - SYNB1934, an evolved strain of SYNB1618, has the potential to provide increased benefit to patients living with PKU - - SYNB1934 Phase 1 Study to evaluate safety, t ...

2021-05-13 - Synlogic Reports First Quarter Financial Results and Provides Business Update

CAMBRIDGE, Mass., May 13, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the first quarter ended March 31, 2021, and provided an update on its clinical and ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15M104100%N/A
#2
$36.4M104-7%N/A
#3
$17.4M104-33%$434.6M
#4
$21.1M105-9%N/A
#5
$21.1M105-49%N/A

Synlogic Therapeutics Funding

DateAmountRoundLead InvestorsReference
2014-10-08$5.0MABill & Melinda GatesArticle
2016-02-18$40.0MBOrbiMed HealthCare Fund ManagementArticle
2017-05-17$42.0MCMultipleArticle
2018-01-25$UndisclosedUndisclosedLeerink PartnersArticle
2018-04-09$30.0MUndisclosedLeerink PartnersArticle